Roseburia Strains for Obesity Treatment via Gut Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating and preventing obesity and related diseases, such as diabetes, are either ineffective or come with significant side effects, and there is a need for a non-toxic and more effective approach.
Innovation Solution
The use of Roseburia bacterial strains, specifically Roseburia inulinivorans DSM 16841, in compositions for pharmaceutical, food, or animal feed to inhibit body weight growth, reduce blood glucose levels, and improve glucose tolerance, which are administered in various forms including tablets, capsules, and emulsions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drug therapy is used to treat obesity and obesity-related diseases, then weight loss and disease control can be achieved, but side effects such as drug allergies, immune resistance, and complications from insulin response occur
Solution Approach 1:
The patent uses probiotics (specifically Lactobacillus and Bifidobacterium strains) as intermediary agents to mediate the treatment of obesity and related diseases. These probiotics act as biological mediators that modulate the gut microbiota composition and function, thereby improving metabolic health, insulin sensitivity, and glucose tolerance without the harmful side effects of conventional drugs. The probiotics serve as a safe intermediary between the host and the metabolic dysfunctions associated with obesity.
2Duration of action of stationary object
If diet-exercise therapy is used for obesity treatment, then long-term weight management can be achieved, but adherence is difficult to maintain and results are not successful for the general public
Solution Approach 1:
The patent employs probiotics that automatically colonize the gut and provide therapeutic effects without requiring active participation or adherence from the patient. Once administered, these microorganisms self-replicate and continuously exert their metabolic benefits, such as improving insulin sensitivity and reducing inflammation, thereby eliminating the need for long-term behavioral changes or dietary restrictions that are difficult to maintain.
3Reliability
If exogenous insulin is used for diabetes patients, then blood glucose control can be achieved, but the treatment is expensive and causes complications such as insulin response (low blood sugar)
Solution Approach 1:
The patent uses specific probiotic strains that naturally produce short-chain fatty acids and other metabolites which improve insulin sensitivity and glucose metabolism endogenously. This self-service mechanism allows the body to regulate its own blood glucose levels more effectively without external insulin injection, thereby avoiding hypoglycemia and other complications associated with exogenous insulin therapy.
4Productivity
If surgical removal of body fat is performed, then immediate weight loss results can be achieved, but surgical risks, difficult to sustain effects, and high cost are involved
Solution Approach 1:
The patent replaces the mechanical/surgical approach of physically removing fat with a biological approach using probiotics. The probiotic strains modify the gut microbiota to influence metabolism, reduce fat accumulation, and improve overall metabolic health through biochemical mechanisms rather than physical removal. This substitution eliminates surgical risks while providing sustained effects through continuous biological activity.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present disclosure provides a use of Roseburia in the preparation of composition for prevention and/or treatment of obesity related diseases. Also provided are a composition used in the treatment and prevention for obesity related diseases, comprising pharmaceutical, drink, food, or animal feed composition, etc; and a method of reducing body weight and/or blood glucose.